StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The failure of KALA's key trial directly impacts investor confidence. Historical precedents show stocks can plummet after major trial failures, as seen with other biotech firms.
What happened, with direct paths to the underlying reporting
KALA halted development of KPI-012 after trial failure. CHASE Phase 2b trial failed to meet primary endpoint. Company plans workforce reductions and cost-saving measures. KALA's stock fell 91.44% to $1.63 after the announcement. It has cash reserves to fund operations until Q1 2026.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.